{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:14:40Z","timestamp":1790673280377,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T00:00:00Z","timestamp":1614384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T00:00:00Z","timestamp":1614384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Rheumatol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Systemic sclerosis (SSc) is a clinically complex and challenging disease, that leads to skin fibrosis. Its most frequent complication is interstitial lung disease (ILD), which leads to a worse prognosis. In this situation, cyclophosphamide is considered the gold standard for its treatment, despite the controversies regarding its efficacy and toxicity. However, studies using rituximab (RTX) have shown that this drug may be a promising therapeutic option.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>This paper objective was to analyze the scientific evidence on the RTX effects on SSc.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A systematic review (SR) was performed including clinical trials (CTs) on the use of RTX in SSc, published up to May 2020. The studies were identified through systematic searches in bibliographic databases using a predefined search strategy. The following databases were used: PUBMED, SCOPUS, SCIELO, LILACS, SCIENCE DIRECT, WEB OF SCIENCE, COCHRANE, WHOLIS, PAHO and EMBASE. Also, a manual search was performed. The methodological quality of the studies was determined using Jadad scale, Risk of Bias Tool (RoB 2.0) and Risk of Bias in Non-Randomized Studies - of Interventions tool (ROBINS-I). A meta-analysis of the randomized CTs was performed, using Review Manager.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Ten CTs were included in this SR. Of these, three were randomized and seven were non-randomized. Five showed a statistically significant improvement in forced vital capacity (FVC) at some time during follow-up. Regarding the skin, eight studies showed statistically significant improvements according toa the modified Rodnan skin score. The meta-analysis found positive effects of RTX in SSc, with a statistical significance for lung disease.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Rituximab is a promising strategy for the SSc-associated ILD and cutaneous fibrosis treatment.<\/jats:p>\n                <jats:p><jats:bold>PROSPERO registration number:<\/jats:bold> CRD42019132018.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s42358-021-00170-y","type":"journal-article","created":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T10:03:36Z","timestamp":1614420216000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Is rituximab effective for systemic sclerosis? A systematic review and meta-analysis"],"prefix":"10.1186","volume":"61","author":[{"given":"Marina Maria Vieira","family":"de Figueiredo Caldas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7849-2661","authenticated-orcid":false,"given":"Kesley Pablo Morais","family":"de Azevedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Clara","family":"de Fran\u00e7a Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor Hugo","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isac Davidson Santiago Fernandes","family":"Pimenta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabela Dantas Torres","family":"de Ara\u00fajo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Alves Bezerra","family":"Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Katherine","family":"da Silveira Gon\u00e7alves de Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grasiela","family":"Piuvezam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,27]]},"reference":[{"issue":"2","key":"170_CR1","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1097\/BOR.0b013e32834ff2e8","volume":"24","author":"J Barnes","year":"2012","unstructured":"Barnes J, Mayes MD. Epidemiology of systemic sclerosis: incidence, prevalence, survival, risk factors, malignancy, and environmental triggers. Curr Opin Rheumatol. 2012;24(2):165\u201370.","journal-title":"Curr Opin Rheumatol"},{"issue":"6","key":"170_CR2","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.semarthrit.2016.12.003","volume":"46","author":"RE Pellar","year":"2017","unstructured":"Pellar RE, Pope JE. Evidence-based management of systemic sclerosis: navigating recommendations and guidelines. Semin Arthritis Rheum [Internet]. 2017;46(6):767\u201374 Available from: https:\/\/www.scopus.com\/inward\/record.uri?eid=2-s2.0-85009495497&doi=10.1016%2Fj.semarthrit.2016.12.003&partnerID=40&md5=5bcdb25b18503678add9e44831c471d4.","journal-title":"Semin Arthritis Rheum [Internet]."},{"issue":"SUPPL. 1","key":"170_CR3","doi-asserted-by":"publisher","first-page":"S59","DOI":"10.1016\/j.rmed.2010.03.018","volume":"104","author":"L Mouthon","year":"2010","unstructured":"Mouthon L, B\u00e9rezn\u00e9 A, Guillevin L, Valeyre D. Therapeutic options for systemic sclerosis related interstitial lung diseases. Respir Med. 2010;104(SUPPL. 1):S59\u201369.","journal-title":"Respir Med"},{"issue":"5","key":"170_CR4","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.autrev.2010.09.012","volume":"10","author":"G Bussone","year":"2011","unstructured":"Bussone G, Mouthon L. Interstitial lung disease in systemic sclerosis. Autoimmun Rev. 2011;10(5):248\u201355.","journal-title":"Autoimmun Rev"},{"key":"170_CR5","doi-asserted-by":"publisher","unstructured":"Bosello S, De Santis M, Lama G, Span\u00f2 C, Angelucci C, Tolusso B, et al. B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial. Arthritis Res Ther [Internet]. 2010 [cited 2018 Jan 8];12(2):R54. Available from: http:\/\/arthritis-research.biomedcentral.com\/articles\/https:\/\/doi.org\/10.1186\/ar2965","DOI":"10.1186\/ar2965"},{"issue":"10","key":"170_CR6","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1093\/rheumatology\/key175","volume":"57","author":"N Pittman","year":"2018","unstructured":"Pittman N, Rawn SM, Wang M, Masetto A, Beattie KA, Larch\u00e9 M. Treatment of small intestinal bacterial overgrowth in systemic sclerosis: a systematic review. Rheumatology. 2018;57(10):1802\u201311.","journal-title":"Rheumatology."},{"key":"170_CR7","doi-asserted-by":"publisher","unstructured":"Allanore Y. Avanc\u00e9es th\u00e9rapeutiques dans l\u2019atteinte interstitielle pulmonaire au cours de la scl\u00e9rodermie syst\u00e9mique. Rev du Rhum Monogr 2018;85(3):165\u2013170. doi:https:\/\/doi.org\/https:\/\/doi.org\/10.1016\/j.monrhu.2018.02.003.","DOI":"10.1016\/j.monrhu.2018.02.003"},{"key":"170_CR8","doi-asserted-by":"publisher","unstructured":"Hax V, Bredemeier M, Didonet Moro AL, Pavan TR, Vieira MV, Pitrez EH, et al. Clinical algorithms for the diagnosis and prognosis of interstitial lung disease in systemic sclerosis. Semin Arthritis Rheum [Internet] 2017;47(2):228\u2013234. Available from: http:\/\/dx.doi.org\/https:\/\/doi.org\/10.1016\/j.semarthrit.2017.03.019","DOI":"10.1016\/j.semarthrit.2017.03.019"},{"issue":"5","key":"170_CR9","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.autrev.2016.01.007","volume":"15","author":"AC Desbois","year":"2016","unstructured":"Desbois AC, Cacoub P. Systemic sclerosis: an update in 2016. Autoimmun Rev. 2016;15(5):417\u201326.","journal-title":"Autoimmun Rev"},{"key":"170_CR10","doi-asserted-by":"crossref","unstructured":"Volkmann ER, Tashkin DP, Sim M, Li N, Goldmuntz E, Keyes-Elstein L, et al. Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts. Ann Rheum Dis. 2018:122\u201330.","DOI":"10.1136\/annrheumdis-2018-213708"},{"issue":"00","key":"170_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/17843286.2018.1521904","volume":"00","author":"N Berghen","year":"2018","unstructured":"Berghen N, Vulsteke J, Westhovens R, et al. Rituximab in systemic autoimmune rheumatic diseases : indications and practical use practical use. Acta Clin Belg. 2018;00(00):1\u20138. https:\/\/doi.org\/10.1080\/17843286.2018.1521904.","journal-title":"Acta Clin Belg"},{"issue":"5","key":"170_CR12","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.semarthrit.2016.10.003","volume":"46","author":"D Daoussis","year":"2017","unstructured":"Daoussis D, Melissaropoulos K, Sakellaropoulos G, Antonopoulos I, Markatseli TE, Simopoulou T, et al. A multicenter, open-label, comparative study of B-cell depletion therapy with rituximab for systemic sclerosis-associated interstitial lung disease. Semin Arthritis Rheum [Internet]. 2017;46(5):625\u201331 Available from: https:\/\/www.scopus.com\/inward\/record.uri?eid=2-s2.0-85006271564&doi=10.1016%2Fj.semarthrit.2016.10.003&partnerID=40&md5=157c14914cef5ccd551dd3500113b555.","journal-title":"Semin Arthritis Rheum [Internet]."},{"issue":"8","key":"170_CR13","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","volume":"76","author":"O Kowal-Bielecka","year":"2017","unstructured":"Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76(8):1327\u201339.","journal-title":"Ann Rheum Dis"},{"key":"170_CR14","doi-asserted-by":"publisher","unstructured":"Adler S, Huscher D, Siegert E, et al. Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: Results of the EUSTAR group. Arthritis Res Ther. 2018;20(1). doi:https:\/\/doi.org\/10.1186\/s13075-018-1517-z","DOI":"10.1186\/s13075-018-1517-z"},{"key":"170_CR15","doi-asserted-by":"crossref","unstructured":"Daoussis D, Tsamandas A, Antonopoulos I, Filippopoulou A, Papachristou DJ, Papachristou NI, et al. B cell depletion therapy upregulates Dkk-1 skin expression in patientswith systemic sclerosis: association with enhanced resolution of skinfibrosis. Arthritis Res Ther. 2016;18.","DOI":"10.1186\/s13075-016-1017-y"},{"key":"170_CR16","doi-asserted-by":"publisher","unstructured":"Bosello SL, De Luca G, Rucco M, Berardi G, Falcione M, Danza FM, et al. Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis. Semin Arthritis Rheum [Internet]. 2015;44(4):428\u2013436. Available from: http:\/\/dx.doi.org\/https:\/\/doi.org\/10.1016\/j.semarthrit.2014.09.002","DOI":"10.1016\/j.semarthrit.2014.09.002"},{"issue":"2","key":"170_CR17","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1093\/rheumatology\/kep093","volume":"49","author":"D Daoussis","year":"2010","unstructured":"Daoussis D, Liossis SNC, Tsamandas AC, Kalogeropoulou C, Kazantzi A, Sirinian C, et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology. 2010;49(2):271\u201380.","journal-title":"Rheumatology."},{"key":"170_CR18","doi-asserted-by":"crossref","unstructured":"Caldas MMV de F, Neto FAB, Azevedo KPM de, Pimenta IDSF, Oliveira AKDSG De, Piuvezam G. Rituximab in systemic sclerosis: A protocol for systematic review. Medicine (Baltimore). 2019;98(38). https:\/\/journals.lww.com\/md-journal\/Fulltext\/2019\/09200\/Rituximab_in_systemic_sclerosis__A_protocol_for.18.aspx.","DOI":"10.1097\/MD.0000000000017110"},{"issue":"9","key":"170_CR19","doi-asserted-by":"publisher","first-page":"889","DOI":"10.3736\/jcim20090918","volume":"7","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement (Chinese edition). J Chinese Integr Med. 2009;7(9):889\u201396. https:\/\/doi.org\/10.3736\/jcim20090918.","journal-title":"J Chinese Integr Med"},{"key":"170_CR20","doi-asserted-by":"publisher","unstructured":"Hoogen F Van Den, Khanna D, Fransen J, et al. Arthritis & Rheumatism 2013 Classification Criteria for Systemic Sclerosis. 2013;65(11):2737\u20132747. doi:https:\/\/doi.org\/10.1002\/art.38098.","DOI":"10.1002\/art.38098"},{"issue":"7","key":"170_CR21","first-page":"1573","volume":"28","author":"EC LeRoy","year":"2001","unstructured":"LeRoy EC, Medsger TAJ. Criteria for the classification of early systemic sclerosis. J Rheumatol. 2001;28(7):1573\u20136.","journal-title":"J Rheumatol"},{"issue":"1","key":"170_CR22","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4.","journal-title":"Syst Rev"},{"key":"170_CR23","doi-asserted-by":"publisher","unstructured":"Stephen H. Halpern MJD. Jadad scale for reporting randomized controlled trials Many. Evidence-based Obstet Anesth [Internet]. 2005;237\u20138. Available from: http:\/\/onlinelibrary.wiley.com\/doi\/https:\/\/doi.org\/10.1002\/9780470988343.app1\/pdf","DOI":"10.1002\/9780470988343.app1\/pdf"},{"key":"170_CR24","doi-asserted-by":"publisher","unstructured":"Higgins JPT, Altman DG, G\u00f8tzsche PC, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343. https:\/\/doi.org\/10.1136\/bmj.d5928.","DOI":"10.1136\/bmj.d5928"},{"key":"170_CR25","doi-asserted-by":"publisher","unstructured":"Sterne JAC, Hern\u00e1n MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355. https:\/\/doi.org\/10.1136\/bmj.i4919.","DOI":"10.1136\/bmj.i4919"},{"key":"170_CR26","unstructured":"Review Manager (RevMan) [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014."},{"key":"170_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2016-000384","volume":"3","author":"M Boonstra","year":"2017","unstructured":"Boonstra M, Meijs J, Dorj\u00e9e AL, et al. Rituximab in early systemic sclerosis. RMD Open. 2017;3:e000384. https:\/\/doi.org\/10.1136\/rmdopen-2016-000384.","journal-title":"RMD Open"},{"key":"170_CR28","unstructured":"Sircar G, Goswami RP, Sircar D, Ghosh A, Ghosh P. Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: Open label, randomized, controlled trial. Rheumatol (United Kingdom) [Internet]. 2018;57(12):2106\u201313. Available from: https:\/\/www.scopus.com\/inward\/record.uri?eid=2-s2.0-85057264332&doi=10.1093%2Frheumatology%2Fkey213&partnerID=40&md5=efd115c63c163b9bb928cc2218de7e64"},{"issue":"2","key":"170_CR29","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/art.24249","volume":"60","author":"R Lafyatis","year":"2009","unstructured":"Lafyatis R, Kissin E, York M, Farina G, Viger K, Fritzler MJ, et al. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum. 2009;60(2):578\u201383.","journal-title":"Arthritis Rheum"},{"key":"170_CR30","doi-asserted-by":"publisher","unstructured":"Melsens K, Vandecasteele E, Deschepper E, Badot V, Blockmans D, Brusselle G, et al. Two years follow-up of an open-label pilot study of treatment with rituximab in patients with early diffuse cutaneous systemic sclerosis. Acta Clin Belg [Internet]. 2017 11 [cited 2018 Jan 8];1\u20137. Available from: https:\/\/www.tandfonline.com\/doi\/full\/https:\/\/doi.org\/10.1080\/17843286.2017.1372244","DOI":"10.1080\/17843286.2017.1372244"},{"key":"170_CR31","doi-asserted-by":"publisher","unstructured":"Smith V, Van Praet JT, Vandooren B, Van der Cruyssen B, Naeyaert J-M, Decuman S, et al. Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis [Internet]. 2010 Jan Jan;69(1):193\u20137. [cited 2018 Jan 8];69(1):193\u20137. Available from: http:\/\/ard.bmj.com\/cgi\/doi\/https:\/\/doi.org\/10.1136\/ard.2008.095463","DOI":"10.1136\/ard.2008.095463"},{"issue":"1","key":"170_CR32","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3899\/jrheum.120778","volume":"40","author":"V Smith","year":"2013","unstructured":"Smith V, Piette Y, Van Praet JT, Decuman S, Deschepper E, Elewaut D, et al. Two-year results of an open pilot study of a 2-treatment course with rituximab in patients with early systemic sclerosis with diffuse skin involvement. J Rheumatol. 2013;40(1):52\u20137.","journal-title":"J Rheumatol"},{"issue":"10","key":"170_CR33","first-page":"1520","volume":"18","author":"JH Warrick","year":"1991","unstructured":"Warrick JH, Bhalla M, Schabel SI, Silver RM. High resolution computed tomography in early scleroderma lung disease. J Rheumatol [Internet]. 1991;18(10):1520\u20138 Available from: http:\/\/europepmc.org\/abstract\/MED\/1765976.","journal-title":"J Rheumatol [Internet]"},{"key":"170_CR34","doi-asserted-by":"publisher","first-page":"977","DOI":"10.2214\/ajr.169.4.9308447","volume":"169","author":"EA Kazerooni","year":"1997","unstructured":"Kazerooni EA, Martinez FJ, Flint A, Jamadar DA, Gross BH, Spizarny DL, et al. Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. AJR Am J Roentgenol. 1997;169:977\u201383.","journal-title":"AJR Am J Roentgenol"},{"key":"170_CR35","doi-asserted-by":"publisher","unstructured":"Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med [Internet] 2006;354(25):2655\u20132666. Available from: http:\/\/www.nejm.org\/doi\/abs\/https:\/\/doi.org\/10.1056\/NEJMoa055120","DOI":"10.1056\/NEJMoa055120"},{"issue":"12","key":"170_CR36","doi-asserted-by":"publisher","first-page":"3962","DOI":"10.1002\/art.22204","volume":"54","author":"RK Hoyles","year":"2006","unstructured":"Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NSL, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 2006;54(12):3962\u201370.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"170_CR37","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1093\/rheumatology\/35.4.364","volume":"35","author":"FH Van den Hoogen","year":"1996","unstructured":"Van den Hoogen FH, Boerbooms AM, Swaak AJ, et al. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol. 1996;35(4):364\u201372 Available from: http:\/\/cochranelibrary-wiley.com\/o\/cochrane\/clcentral\/articles\/651\/CN-00124651\/frame.html.","journal-title":"Br J Rheumatol"},{"issue":"6","key":"170_CR38","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1002\/1529-0131(200106)44:6<1351::AID-ART227>3.0.CO;2-I","volume":"44","author":"JE Pope","year":"2001","unstructured":"Pope JE, Bellamy N, Seibold JR, Baron M, Ellman M, Carette S, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum. 2001;44(6):1351\u20138.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"170_CR39","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1517\/14740338.4.4.723","volume":"4","author":"O Lateef","year":"2005","unstructured":"Lateef O, Shakoor N, Balk RA. Methotrexate pulmonary toxicity. Expert Opin Drug Saf. 2005;4(4):723\u201330.","journal-title":"Expert Opin Drug Saf"},{"issue":"6","key":"170_CR40","doi-asserted-by":"publisher","first-page":"791","DOI":"10.2165\/00003495-200666060-00005","volume":"66","author":"RS Cvetkovi\u0107","year":"2006","unstructured":"Cvetkovi\u0107 RS, Perry CM. Rituximab: a review of its use in non-Hodgkin\u2019s lymphoma and chronic lymphocytic leukaemia. Drugs. 2006;66(6):791\u2013820.","journal-title":"Drugs."},{"key":"170_CR41","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1093\/rheumatology\/keq310","volume":"50","author":"M Bassel","year":"2011","unstructured":"Bassel M, Hudson M, Taillefer SS, Schieir O, Baron M, Thombs BD. Frequency and impact of symptoms experienced by patients with systemic sclerosis: results from a Canadian national survey. Rheumatology. 2011;50:762\u20137.","journal-title":"Rheumatology."},{"key":"170_CR42","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1093\/rheumatology\/ken455","volume":"48","author":"SB Sandusky","year":"2009","unstructured":"Sandusky SB, McGuire L, Smith MT, Wigley FM, Haythornthwaite JA. Fatigue: An overlooked determinant of physical function in scleroderma. Rheumatology. 2009;48:165\u20139.","journal-title":"Rheumatology."},{"key":"170_CR43","doi-asserted-by":"crossref","unstructured":"Murphy SL, Kratz AL, Whibley D, Poole JL, Khanna D. Fatigue and its association with social participation, functioning, and quality of life in systemic sclerosis. Arthritis Care Res. 2019;1:1\u201322.","DOI":"10.1002\/acr.24122"},{"issue":"12","key":"170_CR44","doi-asserted-by":"publisher","first-page":"3347","DOI":"10.1007\/s11136-019-02284-9","volume":"28","author":"M Sierakowska","year":"2019","unstructured":"Sierakowska M, Doroszkiewicz H, Sierakowska J, et al. Factors associated with quality of life in systemic sclerosis: a cross-sectional study. Qual Life Res. 2019;28(12):3347\u201354. https:\/\/doi.org\/10.1007\/s11136-019-02284-9.","journal-title":"Qual Life Res"},{"key":"170_CR45","doi-asserted-by":"publisher","first-page":"685","DOI":"10.3899\/jrheum.100635","volume":"38","author":"M Schnitzer","year":"2010","unstructured":"Schnitzer M, Hudson M, Baron M, Steele R. Disability in systemic sclerosis-a longitudinal observational study. J Rheumatol. 2010;38:685\u201392.","journal-title":"J Rheumatol"},{"issue":"87","key":"170_CR46","doi-asserted-by":"publisher","first-page":"106389","DOI":"10.1016\/j.intimp.2020.106389","volume":"83","author":"R Tang","year":"2020","unstructured":"Tang R, Yu J, Shi Y, et al. Safety and efficacy of rituximab in systemic sclerosis : a systematic review and meta-analysis. Int Immunopharmacol. 2020;83(87):106389. https:\/\/doi.org\/10.1016\/j.intimp.2020.106389.","journal-title":"Int Immunopharmacol"}],"container-title":["Advances in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-021-00170-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s42358-021-00170-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-021-00170-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T10:13:28Z","timestamp":1614420808000},"score":1,"resource":{"primary":{"URL":"https:\/\/advancesinrheumatology.biomedcentral.com\/articles\/10.1186\/s42358-021-00170-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,27]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["170"],"URL":"https:\/\/doi.org\/10.1186\/s42358-021-00170-y","relation":{},"ISSN":["2523-3106"],"issn-type":[{"value":"2523-3106","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,27]]},"assertion":[{"value":"6 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval and informed consent are not necessary for this research, because it is a systematic review (use of secondary data).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15"}}